RSCM
INZY
Rock Springs Capital Management’s Inozyme Pharma INZY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,445,299
| Closed | -$3.14M | – | 96 |
|
|
2025
Q1 | $3.14M | Sell |
3,445,299
-416,684
| -11% | -$379K | 0.18% | 72 |
|
|
2024
Q4 | $10.7M | Buy |
3,861,983
+59,100
| +2% | +$164K | 0.41% | 60 |
|
|
2024
Q3 | $19.9M | Buy |
3,802,883
+104,509
| +3% | +$547K | 0.65% | 51 |
|
|
2024
Q2 | $16.5M | Buy |
3,698,374
+17,200
| +0.5% | +$76.7K | 0.5% | 55 |
|
|
2024
Q1 | $28.2M | Hold |
3,681,174
| – | – | 0.72% | 48 |
|
|
2023
Q4 | $15.7M | Hold |
3,681,174
| – | – | 0.39% | 63 |
|
|
2023
Q3 | $15.5M | Buy |
3,681,174
+253,090
| +7% | +$1.06M | 0.41% | 64 |
|
|
2023
Q2 | $19.1M | Buy |
3,428,084
+213,184
| +7% | +$1.19M | 0.45% | 58 |
|
|
2023
Q1 | $18.4M | Buy |
3,214,900
+128,873
| +4% | +$738K | 0.44% | 59 |
|
|
2022
Q4 | $3.24M | Buy |
3,086,027
+278,409
| +10% | +$292K | 0.08% | 97 |
|
|
2022
Q3 | $7.52M | Buy |
2,807,618
+167,562
| +6% | +$449K | 0.19% | 89 |
|
|
2022
Q2 | $12.6M | Buy |
2,640,056
+1,446,861
| +121% | +$6.9M | 0.37% | 68 |
|
|
2022
Q1 | $4.88M | Buy |
1,193,195
+324,729
| +37% | +$1.33M | 0.12% | 105 |
|
|
2021
Q4 | $5.92M | Buy |
868,466
+18,451
| +2% | +$126K | 0.14% | 114 |
|
|
2021
Q3 | $9.85M | Buy |
850,015
+9,743
| +1% | +$113K | 0.21% | 106 |
|
|
2021
Q2 | $14.3M | Buy |
840,272
+12,372
| +1% | +$211K | 0.28% | 96 |
|
|
2021
Q1 | $16.4M | Sell |
827,900
-2,646
| -0.3% | -$52.4K | 0.36% | 79 |
|
|
2020
Q4 | $17.1M | Sell |
830,546
-49,408
| -6% | -$1.02M | 0.36% | 84 |
|
|
2020
Q3 | $23.1M | Buy |
+879,954
| New | +$23.1M | 0.59% | 57 |
|